Cancer immunology and immunotherapy

Código QR

Cancer immunology and immunotherapy

Guardado en:

Detalles Bibliográficos
Autor principal:	Xiubao Ren
Formato:	article
Lenguaje:	EN
Publicado:	China Anti-Cancer Association 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e2f44bd30ce1452e8f783f7382fc9e88
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Cancer Immunology and Immunotherapies: Mechanisms That Affect Antitumor Immune Response and Treatment Resistance
por: Xianda Zhao, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
por: Amaia Lujambio, et al.
Publicado: (2021)

Novel emerging biomarkers to immunotherapy in kidney cancer
por: Yasser Ged, et al.
Publicado: (2021)

Immunotherapy in breast cancer: A clinician's perspective
por: Sibapriya Chaudhuri, et al.
Publicado: (2021)

Simple and effective bacterial-based intratumoral cancer immunotherapy
por: Teresa Neeman, et al.
Publicado: (2021)

Dramatic response of metaplastic breast cancer to chemo-immunotherapy
por: Sylvia Adams
Publicado: (2017)

The role of DLL1 in long-term vascular normalization and cancer immunotherapy
por: Qiaozhen Wu, et al.
Publicado: (2021)

Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy
por: Mingdong Lu, et al.
Publicado: (2021)

Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
por: Martin Thelen, et al.
Publicado: (2021)

Leveraging the Treg-intrinsic CTLA4–PKCη signaling pathway for cancer immunotherapy
por: Hsin-Yu Liu, et al.
Publicado: (2021)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Hong-fen Guo, et al.
Publicado: (2021)

A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
por: Xi Jiao, et al.
Publicado: (2021)

Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies
por: Andrew Wallace, et al.
Publicado: (2021)

Epithelial cells mimic immune cells: a novel path toward tumor immunotherapy
por: Ruining Gong, et al.
Publicado: (2021)

The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response
por: Guangyu Wang, et al.
Publicado: (2021)

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
por: Michael Dougan, et al.
Publicado: (2021)

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Chao Liu, et al.
Publicado: (2021)

Correction: THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
Publicado: (2021)

Correction: Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
Publicado: (2021)

Correction: Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
Publicado: (2021)

Correction: Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer
Publicado: (2021)

Correction: Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations
Publicado: (2021)

Immunological configuration of ovarian carcinoma: features and impact on disease outcome
por: Lorenzo Galluzzi, et al.
Publicado: (2021)

Transcriptional suppression of CD8+ T cell exhaustion for improving T cell immunotherapy
por: Xue Yang, et al.
Publicado: (2021)

Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer
por: Wallace Akerley, et al.
Publicado: (2021)

Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment
por: Naixue Yang, et al.
Publicado: (2021)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
por: Min Yu, et al.
Publicado: (2021)

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Thomas F Gajewski, et al.
Publicado: (2021)

Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting
por: Matthew M Seavey, et al.
Publicado: (2009)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2021)

Correction: Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
Publicado: (2021)

Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity
por: Elizabeth Repasky, et al.
Publicado: (2021)

Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.
por: Vincenzo Mazzaferro, et al.
Publicado: (2021)

Correction: Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity
Publicado: (2021)

Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
por: Chuan HUANG, et al.
Publicado: (2021)

Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
por: Theresa L Walunas, et al.
Publicado: (2021)

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
por: Haiying Qin, et al.
Publicado: (2021)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Sjoerd H van der Burg, et al.
Publicado: (2021)

Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
por: Jia Chen, et al.
Publicado: (2021)

Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer
por: Xi Yang, et al.
Publicado: (2021)